Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Bod Science's Pre-Tax Income for the
six
months ended in Jun. 2025 was A$0.28 Mil. Bod Science's Revenue for the
six
months ended in Jun. 2025 was A$0.88 Mil. Therefore, Bod Science's pretax margin for the quarter that ended in Jun. 2025 was 31.11%.
The historical rank and industry rank for Bod Science's Pretax Margin % or its related term are showing as below:
ASX:BOD'
s Pretax Margin % Range Over the Past 10 Years
Min: -929.76 Med: -430.48 Max: 17.44
Current: 17.44
ASX:BOD's Pretax Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.295
vs ASX:BOD: 17.44
Bod Science (ASX:BOD) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Bod Science Pretax Margin % Related Terms
Bod Science Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Bod Science's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bod Science Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bod Science's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Bod Science's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bod Science (ASX:BOD) has a Pretax Margin % of 31.11% as of Jun. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bod Science and its competitors.
Is Bod Science's Pretax Margin % too high?
Bod Science's current Pretax Margin % is 31.11%. The Drug Manufacturers industry median Pretax Margin % is 7.30. Bod Science's value of 31.11% is 326.5% above this industry median. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's Pretax Margin % compare to ZTS?
Bod Science's Pretax Margin % of 31.11% can be compared against companies in the Drug Manufacturers industry. The industry median Pretax Margin % is 7.30. Bod Science's value of 31.11% is 326.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bod Science's current Pretax Margin % of 31.11% is 326.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current Pretax Margin % is 31.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current Pretax Margin % of 31.11%. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current Pretax Margin % is 31.11% and 326.5% above the Drug Manufacturers industry median of 7.30. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current Pretax Margin % is 31.11% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bod Science (ASX:BOD) Overvalued in 2026?
Based on GuruFocus' analysis, Bod Science stock appears to be undervalued.
The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.
Key valuation signals for ASX:BOD:
Pretax Margin %: 31.11%
GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
Industry Position: 326.5% above the Drug Manufacturers median
No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score
Get the complete analysis for ASX:BOD
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOD has been successfully added to your 
